Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A multicenter open label phase II study of to assess the efficacy and safety of APO866 [daporinad] in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma

Next Previous
X
Search
Trial Profile

A multicenter open label phase II study of to assess the efficacy and safety of APO866 [daporinad] in the treatment of patients with refractory or relapsed cutaneous T-cell lymphoma

Status: Discontinued
Phase of Trial: Phase II

Latest Information Update: 18 Dec 2023

Price :

$35 *

Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Daporinad (Primary)
  • Indications Cutaneous T-cell lymphoma
  • Focus Therapeutic Use
  • Sponsors Valerio Therapeutics

    • Most Recent Events

    • 23 Mar 2016 Results published in the JAMA Dermatology
    • 02 Jun 2015 According to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology, due to lack of efficacy study was stopped after enrolment of 14 patients.
    • 02 Jun 2015 Primary endpoint has not been met. (The proportion of eligible patients with refractory or relapsed CTCL whom have a complete response or partial response on cutaneous lesions (Tumor Burden Index) and extra-cutaneous disease.), according to an abstract presented at the 51st Annual Meeting of the American Society of Clinical Oncology.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top